We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Read MoreHide Full Article
Palisade (PALI - Free Report) , a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was up almost 7% on Apr 5 as it announced that its development partner, Newsoara Biopharma, has enrolled the first patient in its ongoing phase III clinical study for LB1148 in China.
The start of patient enrollment in LB1148’s phase III clinical study is an important milestone for Palisade Bio as well as Newsoara. If successful, this could lead to the availability of LB1148 for patients in China, improving postoperative outcomes and reducing the impact of delayed return of bowel function.
LB1148 is a broad-spectrum serine protease inhibitor that aims to neutralize digestive enzymes and potentially reduce intestinal damage. The study is designed as a randomized, double-blinded, placebo-controlled clinical investigation that will enroll patients undergoing scheduled bowel resection surgery using either laparotomy or laparoscopic surgical approaches.
All patients enrolled in the trial will be assessed for their safety and efficacy in accelerating the return of bowel function after surgery.
Shares of Palisade have plunged 95.3% in the past year compared with the industry's 15.9% decline.
Image Source: Zacks Investment Research
Delayed return of bowel function is a common complication after abdominal surgery and impacts millions of patients globally every year. LB1148 has shown the potential to address this complication by neutralizing digestive enzymes and potentially reducing intestinal damage.
The clearance to proceed with phase III in China was received by Newsoara in May 2022.
The effectiveness of LB1148 is also being evaluated in an ongoing phase II study to reduce intra-abdominal adhesions, accelerate return of gastrointestinal function and prevent post-operative ileus in patients undergoing elective bowel resection.
Under the existing agreement, Newsoara is responsible for fully performing and funding the development of LB1148 in China, including this phase III study. The company will also make milestone payments to Palisade upon achieving certain clinical, regulatory and commercial milestones. It will also make tiered royalty payments on any future annual net sales of LB1148 in greater China.
Management believes that the drug can improve postoperative outcomes by accelerating the postoperative return of GI function and reducing post-surgical adhesions. Therefore, the company's team is focused on executing its development plans to advance toward successful completion of the study and data readout.
Loss per share estimates for CRISPR have narrowed from $8.21 to $7.35 for 2023 in the past 60 days.
The company's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP's shares have plunged 29.9% in the past year.
Loss per share estimates for Kala have narrowed from $19.67 to $15.35 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. The company's shares have plunged 74.3% in the past year.
KALA's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
Loss per share estimates for Kodiak Sciences have narrowed from $5.66 to $5.3 for 2023 and from $5.18 to $4.71 for 2024 in the past 60 days.
The company's earnings beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 0.96%. KOD's shares have plunged 35% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Palisade (PALI - Free Report) , a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was up almost 7% on Apr 5 as it announced that its development partner, Newsoara Biopharma, has enrolled the first patient in its ongoing phase III clinical study for LB1148 in China.
The start of patient enrollment in LB1148’s phase III clinical study is an important milestone for Palisade Bio as well as Newsoara. If successful, this could lead to the availability of LB1148 for patients in China, improving postoperative outcomes and reducing the impact of delayed return of bowel function.
LB1148 is a broad-spectrum serine protease inhibitor that aims to neutralize digestive enzymes and potentially reduce intestinal damage. The study is designed as a randomized, double-blinded, placebo-controlled clinical investigation that will enroll patients undergoing scheduled bowel resection surgery using either laparotomy or laparoscopic surgical approaches.
All patients enrolled in the trial will be assessed for their safety and efficacy in accelerating the return of bowel function after surgery.
Shares of Palisade have plunged 95.3% in the past year compared with the industry's 15.9% decline.
Image Source: Zacks Investment Research
Delayed return of bowel function is a common complication after abdominal surgery and impacts millions of patients globally every year. LB1148 has shown the potential to address this complication by neutralizing digestive enzymes and potentially reducing intestinal damage.
The clearance to proceed with phase III in China was received by Newsoara in May 2022.
The effectiveness of LB1148 is also being evaluated in an ongoing phase II study to reduce intra-abdominal adhesions, accelerate return of gastrointestinal function and prevent post-operative ileus in patients undergoing elective bowel resection.
Under the existing agreement, Newsoara is responsible for fully performing and funding the development of LB1148 in China, including this phase III study. The company will also make milestone payments to Palisade upon achieving certain clinical, regulatory and commercial milestones. It will also make tiered royalty payments on any future annual net sales of LB1148 in greater China.
Management believes that the drug can improve postoperative outcomes by accelerating the postoperative return of GI function and reducing post-surgical adhesions. Therefore, the company's team is focused on executing its development plans to advance toward successful completion of the study and data readout.
Palisade Bio, Inc. Price and Consensus
Palisade Bio, Inc. price-consensus-chart | Palisade Bio, Inc. Quote
Zacks Rank & Other Stocks to Consider
Currently, Palisade has a Zacks Rank #2 (Buy).
Some other top-ranked stocks for investors interested in the same sector are CRISPR Therapeutics (CRSP - Free Report) , Kala Pharmaceuticals (KALA - Free Report) and Kodiak Sciences (KOD - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for CRISPR have narrowed from $8.21 to $7.35 for 2023 in the past 60 days.
The company's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP's shares have plunged 29.9% in the past year.
Loss per share estimates for Kala have narrowed from $19.67 to $15.35 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. The company's shares have plunged 74.3% in the past year.
KALA's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
Loss per share estimates for Kodiak Sciences have narrowed from $5.66 to $5.3 for 2023 and from $5.18 to $4.71 for 2024 in the past 60 days.
The company's earnings beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 0.96%. KOD's shares have plunged 35% in the past year.